Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07602218 · ClinicalTrials.gov registry record · NA
Adaptive Decision Support for Addiction Treatment (ADAPT) Serial Randomized Testing for Usability, Round 2
A NA study, sponsored by Yale University.
- Not yet
- Registry status
- NA
- Development phase
- 300
- Enrollment target
NCT07602218: Clinical Trial NA study, sponsored by Yale University.
NCT07602218 is a NA study that has not yet begun recruiting, run by Yale University. The registered enrollment target is 300 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07602218, a NA study, has not yet begun recruiting, sponsored by Yale University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 300 participants
- Enrollment target
Study Summary
This study is stage 2, round 2 of a larger study which refines and optimizes the EMBED clinical decision support (CDS); see NCT03658642 to increase number of ED physicians following standard of care for the administration of buprenorphine to appropriate patients with opioid use disorder.
Primary Outcome
Proportion of encounters with documentation of a clinician order for an addiction counselor consult specifically to assess for eligibility and initiation of MOUD.
Interventions
- OTHER Refined EMBED CDS
- OTHER Provider alert to order consultation with addiction counselor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-05-21 |
| Est. Completion | 2026-08 |
| Phase | NA |
What is known before NCT07602218 opens enrollment
NCT07602218 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 2 interventions - of which Refined EMBED CDS is the first listed.
NCT07602218 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07602218 about?
NCT07602218 is a clinical study titled "Adaptive Decision Support for Addiction Treatment (ADAPT) Serial Randomized Testing for Usability, Round 2". This study is stage 2, round 2 of a larger study which refines and optimizes the EMBED clinical decision support (CDS); see NCT03658642 to increase number of ED physicians following standard of care for the administration of buprenorphine to appropriate patients with opioid use disorder.
What is the current status of trial NCT07602218?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2026-05-21. Estimated completion is 2026-08.
What interventions are being tested in trial NCT07602218?
The interventions under investigation include: Refined EMBED CDS (OTHER), Provider alert to order consultation with addiction counselor (OTHER).
Who is sponsoring clinical trial NCT07602218?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07602218's enrollment target sits among peer trials
300 330th of 2000 higher than 1,630 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI